A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors
Latest Information Update: 22 Oct 2024
Price :
$35 *
At a glance
- Drugs SHR 7787 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.
- 01 Oct 2024 New trial record